Optimizing a Unique Cancer Vaccine for Intradermal Delivery

Sesay,Muctarr;Tomai,Mark;Fuller,Steven;Price,John;Cunningham,Dave;

Optimizing a Unique Cancer Vaccine for Intradermal Delivery

Published on: September 15, 2017

Muctarr Sesay, Mark Tomai, Steven Fuller, John Price, Dave Cunningham

BioPharm International, BioPharm International-09-15-2017, Volume 2017 eBook, Issue 2

Pages: 31-35

Using a hollow microstructured transdermal system to deliver vaccine directly to the dermis.

3M Drug Delivery Systems and Panacea Pharmaceuticals are collaborating to deliver Panacea’s investigational cancer vaccine, PAN- 301-1, directly to the dermis via the 3M hollow microstructured transdermal system (hMTS).

PAN-301-1 vaccine is a biologic that cannot be administered orally, or via a transdermal patch; therefore, it was thought that intradermal delivery to the skin could potentially be the optimal route of administration. The hMTS offers high-volume, reproducible, direct delivery capability to the highly-vascularized dermis.

Download the

Article Details

BioPharm International eBook: Development Strategies for Emerging Therapies
Vol. 30
September 2017
Pages: 31-35

Citation

When referring to this article, please cite it as S. Fuller et al., "Optimizing a Unique Cancer Vaccine for Intradermal Delivery, " BioPharm International Development Strategies for Emerging Therapies eBook (September 2017).